Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 16/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 16/20 | 0.71 |
| ▸ | MAPT | P10636 | 15/20 | 0.71 |
| ▸ | LMNA | P02545 | 8/20 | 0.67 |
| ▸ | GAA | P10253 | 6/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 6/20 | 0.67 |
| ▸ | HTT | P42858 | 7/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.58 |
| ▸ | POLB | P06746 | 3/20 | 0.58 |
| ▸ | BLM | P54132 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | CCR6 | P51684 | 1/20 | 0.58 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14438981 | 0.82 | MEN1 (0.78) | MEN1KMT2AMAPTLMNAGAA | |
| SCHEMBL11918201 | 0.79 | MAPT (0.98) | MEN1KMT2AMAPTLMNAGAA | |
| SCHEMBL23345478 | 0.76 | MAPT (0.80) | MEN1KMT2AMAPTLMNAGAA | |
| SCHEMBL14502988 | 0.74 | MEN1 (0.83) | MEN1KMT2AMAPTLMNAGAA | |
| SCHEMBL23345484 | 0.74 | MAPT (0.84) | MEN1KMT2AMAPTLMNAGAA | |
| SCHEMBL23345480 | 0.73 | MAPT (0.85) | MEN1KMT2AMAPTLMNAGAA | |
| SCHEMBL14503535 | 0.71 | MEN1 (0.74) | MEN1KMT2AMAPTLMNAGAA | |
| SCHEMBL23345501 | 0.71 | MAPT (0.85) | MEN1KMT2AMAPTLMNAGAA | |
| SCHEMBL7689352 | 0.69 | MAPT (0.78) | MEN1KMT2AMAPTLMNAGAA | |
| SCHEMBL13942699 | 0.69 | KMT2A (0.77) | MEN1KMT2AMAPTLMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030896-B2 | PIKfyve inhibitors | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030896-B2 | PIKfyve inhibitors | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2024-07-09 | — | — | US | disclosed |
| US-20240016810-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS | YUMANITY THERAPEUTICS, INC. | 2024-01-18 | — | — | US | disclosed |
| US-20240016810-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS | YUMANITY THERAPEUTICS, INC. | 2024-01-18 | — | — | US | disclosed |
| US-20210139505-A1 | PIKfyve Inhibitors | Sanford Burnham Prebys Medical Discovery Institute | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030896-B2 | PIKfyve inhibitors | PIKFYVE, PIP4K2B, PIP4K2A | MEN1 1445/4885KMT2A 1410/4885MAPT 3914/4885 |
| US-20210139505-A1 | PIKfyve Inhibitors | PIKFYVE, PIP4K2B, PIP4K2A | MEN1 1445/4885KMT2A 1410/4885MAPT 3914/4885 |
| US-20240016810-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS | TARDBP, PIKFYVE, FUS | MEN1 4321/4885KMT2A 1078/4885MAPT 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.